SENSE TRIAL – HSN1

ONLINE PATIENT INFORMATION DAY (VIA MICROSOFT TEAMS)

SENSE TRIAL – Hereditary Sensory Neuropathy type 1

Published on behalf of Dr Caroline Kramarz

Tuesday 18th April 2023 

3-5pm 

ONLINE PATIENT INFORMATION DAY (VIA MICROSOFT TEAMS) 

SENSE TRIAL 

We are contacting individuals who have been diagnosed with hereditary sensory neuropathy type 1 (HSN1) which is due to a mutation in either the SPTLC1 or SPTLC2 gene. 

We would like to inform you that we are starting a clinical research drug trial at the National Hospital for Neurology & Neurosurgery, London UK. We are specifically investigating a possible treatment for HSN1 called L-serine. This will be called the SENSE trial (Hereditary Sensory Neuropathy Serine trial). 

We hope that the trial will help us to understand whether L-serine is effective in reducing progression of HSN1. 

We would like to invite you to attend an online patient information day where further details about the trial will be provided and you will have the opportunity to ask the research team any questions.  

The meeting will be chaired by Professor Mary M Reilly and Dr Matilde Laura who will be leading the trial.  

This meeting will be held online on 18th April 2023 3-5pm via Microsoft Teams 

Information to Register   

Please contact: 

Dr Caroline Kramarz: caroline.kramarz@nhs.net 

For any other queries, please contact: 

Ms Maria Brezitski, Trial Coordinator: maria.brezitski@nhs.net 

Connect with us

Last Updated: Wednesday 12th April, 2023